Provided by Tiger Fintech (Singapore) Pte. Ltd.

Compass Therapeutics, Inc.

3.00
-0.1500-4.76%
Post-market: 3.010.0100+0.33%19:04 EDT
Volume:662.52K
Turnover:2.02M
Market Cap:414.85M
PE:-7.49
High:3.22
Open:3.20
Low:2.97
Close:3.15
Loading ...

Company Profile

Company Name:
Compass Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
35
Office Location:
80 Guest Street,Suite 601,Boston,Massachusetts,United States
Zip Code:
02135
Fax:
- -
Introduction:
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.